Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2026)

Allogene Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 315927.27% in Q1 2024.

• Quarterly EBITDA Margin rose 1437939.0% year-over-year to 315927.27% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 1241813.64% (down 89682732.0% YoY) and the FY2024 annual result came in at 1241813.64%, down 89682732.0% from the prior year.
• EBITDA Margin advanced to 315927.27% in Q1 2024 per ALLO's latest filing, from 405280.95% in the prior quarter.
• Over five years, EBITDA Margin peaked at 2.26% in Q4 2021 and troughed at 405280.95% in Q4 2023.
• A 4-year average of 232707.56% and a median of 286345.45% in 2023 frame the typical range for EBITDA Margin.
• The widest YoY moves for EBITDA Margin: up 4171705 bps in 2022, down 37075226 bps in 2022.
• Over 4 years, EBITDA Margin stood at 2.26% in 2021, then plunged by 16431036 bps to 370750.0% in 2022, then dropped by 9 bps to 405280.95% in 2023, then advanced by 22 bps to 315927.27% in 2024.
• According to Business Quant data, EBITDA Margin over the past three periods registered 315927.27%, 405280.95%, and 286345.45% for Q1 2024, Q4 2023, and Q3 2023 respectively.